The following announcement by the Myelin Repair Foundation is particularly of interest to people with MS. But it may also pertain for people who have neuropathic damage to the trigeminal nerve, from other sources.
Regards and best
Red
Today we are extremely pleased to announce that the Myelin Repair Foundation has achieved its goal of a myelin repair Phase 1 clinical trial for multiple sclerosis three years earlier than expected.
This achievement illustrates the effectiveness of our innovative Accelerated Research Collaboration (ARC) Model to advance research forward, moving closer to the development of a myelin repair therapeutic for MS patients. However, even with this incredible success, it is paramount we continue to aggressively push research forward into multiple clinical trials, giving us the best chance of developing an effective myelin repair drug as rapidly as possible.
With our support, MRF Principal Investigator Dr. Robert Miller at Case Western Reserve University's research has now entered into a Phase 1 clinical trial. This trial is being conducted at Cleveland Clinic, examining the efficacy of a new myelin repair therapeutic pathway with mesenchymal stem cells (MSCs).
For more information on the clinical trial and other multiple sclerosis trials in progress, please visit www.clinicaltrials.gov.
As momentous as this milestone is for all of us at MRF and MS patients worldwide, this achievement would not be possible without your generosity. Now more than ever, we need your support to continue to optimize our success. Thank you.
You may read the full clinical trial press release here, or learn more about MRF's recent research breakthroughs by visiting our website at www.myelinrepair.org.
Best regards,
Myelin Repair Foundation Staff